This alignment with the canonical PD‐1/BATF axis reinforces the robustness of our findings and suggests that targeting BATF could be a viable strategy to overcome EV‐mediated immune evasion in HNSCC. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.